TOKYO, October 15, 2019 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) today announced that subsidiaries of Astellas will transfer their marketing authorizations, trademark, and related contracts for “Nasea (5HT3 receptor antagonist-type antiemetic)”, “Perdipine (calcium channel blocker)”, and “Oldeca (sustained release calcium antagonist)” (the “Products”) in Korea, Thailand, the Philippines, Indonesia, China and Taiwan to Daiichi Sankyo Co., Ltd.under an Asset Purchase Agreement concluded between both parties. Closing of the agreement is scheduled in third quarter of the fiscal year 2019.
After closing of the agreement, Astellas will work closely with Daiichi Sankyo to ensure smooth transfer of the Products to continue stable delivery to patients.
Marketing authorization of the Products in Japan, supply business of active ingredients/bulk to third parties in and outside of Japan, as well as the royalty business in Japan has been previously transferred to LTL Pharma Co., Ltd., under the Asset Purchase Agreement in 2017.
- Purpose of Asset Purchase Agreement
The agreement is a part of Astellas’ ongoing efforts to improve the quality and efficiency of operations and to optimize its cost structure so as to accommodate the rapidly changing business environment and achieve sustainable growth. Astellas will further expand our business in Asia region through optimization of resource allocation.
- Financial terms of Asset Purchase Agreement
¥ 9.6 billion
- Schedule of Asset Purchase Agreement
July 31, 2019: Conclusion of the Asset Purchase Agreement
Third quarter of the fiscal year 2019: Closing of the Asset Purchase Agreement (tentative)
After closing of the agreement, marketing authorization of the Products will be transferred in each country. Closing of the agreement shall be subject to fulfillment of the conditions, including obtaining the approval and permission from authorities in each country.
- List of the Products
Formulation Therapeutic Category Target Country Nasea (ramosetron hydrochloride) injection,
5HT3 receptor antagonist-type antiemetic Korea, Thailand, Philippines and Indonesia Perdipine (nicardipine hydrochloride) injection calcium channel blocker China, Korea and Taiwan Oldeca (barnidipine hydrochloride) capsules sustained release calcium antagonist Korea
Sales of the Products: approx. ¥5.0 billion (fiscal year ended March 31, 2019)
- Outline of the succeeding company
Daiichi Sankyo Co., Ltd. (TSE: 4568)
Headquarters: 3-5-1 Nihonbashi-Honcho, Chuo-ku, Tokyo
Representative: President and CEO Sunao Manabe
Operations: Research and development, manufacturing and marketing of pharmaceuticals
The impact from this transaction is not reflected in Astellas' consolidated financial forecasts for the fiscal year ending March 31, 2020 announced in April 2019. Since the consideration for the transfer of the Products is recognized as revenue during the current fiscal year, we expect a positive impact on revenue and operating profit.
Click below for a copy of the full press release